antibody levels and vaccination attitude after asymptomatic to moderate

omniscientis

omniscientis

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

 

Regardless of substantial progress in confronting the worldwide HIV-1 epidemic since its inception within the 1980s, higher approaches for each therapy and prevention will probably be obligatory to finish the epidemic and stay a high public well being precedence. Antiretroviral remedy (ART) has been efficient in extending lives, however at a price of lifelong adherence to therapy. Broadly neutralizing antibodies (bNAbs) are directed to conserved areas of the HIV-1 envelope glycoprotein trimer (Env) and may block an infection if current on the time of viral publicity. The therapeutic software of bNAbs holds nice promise, and progress is being made towards their growth for widespread medical use. In comparison with the present customary of care of small molecule-based ART, bNAbs supply: (1) decreased toxicity; (2) the benefits of prolonged half-lives that might bypass day by day dosing necessities; and (3) the potential to include a wider immune response by Fc signaling. Latest advances in discovery expertise can allow system-wide mining of the immunoglobulin repertoire and can proceed to speed up isolation of subsequent era potent bNAbs. Passive switch research in pre-clinical fashions and medical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and attaining viral suppression.

These research have helped to outline the window of alternative for optimum intervention to realize viral clearance, both utilizing bNAbs alone or together with ART. None of those advances with bNAbs can be doable with out technological developments and increasing the cohorts of donor participation. Collectively these components fueled the exceptional development in bNAb growth. Right here, we evaluation the event of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal fashions and early medical trials, and improvements to optimize their medical potential by efforts to increase half-life, maximize the contribution of Fc effector capabilities, preclude escape by multiepitope concentrating on, and the potential for sustained supply.

 

Signs, antibody ranges and vaccination perspective after asymptomatic to reasonable COVID-19 an infection in 200 healthcare employees

 

Purpose: In Germany, the willingness to be vaccinated towards COVID-19 is slightly low amongst medical workers. We collected information on signs, antibody titers and vaccination readiness from clinic workers at a municipal clinic who had already been by a COVID-19 an infection (asymptomatic to reasonable). We additionally examined the antibody titers for his or her doable significance as a person decision-making assist with regard to vaccination.

 

Technique: 200 workers of our municipal clinics have been included within the research. COVID-19 antibody dedication was carried out utilizing an ELISA (EUROIMMUN™, PerkinElmer, Inc. Firm). The individuals got an nameless questionnaire containing anthropometrical points, signs of the an infection and questions in regards to the vaccination resolution. Lastly, the antibody ranges have been reported to the individuals and the perspective in the direction of a vaccination was reevaluated.

 

Outcomes: In all 200 individuals who had already gone by a COVID-19 an infection, 75 workers have been in favor of a vaccination (37.5%), 96 have been against vaccination (48%), and 29 have been undecided (14.5%). Within the completely different occupational teams, the constructive pattern by way of willingness to be vaccinated was highest amongst physicians and is least amongst nurses. The antibody outcomes confirmed appreciable variation in titer ranges and subsequently didn’t correlate with illness severity in asymptomatic to reasonably in poor health individuals. We additionally noticed a pro-vaccination pattern with rising age of the individuals. The specifically-asked symptom of cutaneous hyperesthesia throughout COVID-19 an infection occurred in 5% of the individuals.

 

Conclusion: In medical personnel who had already suffered from a COVID-19 an infection, the willingness to obtain a vaccination tends to be highest amongst physicians, and lowest in nurses, and will increase with age. For the overwhelming majority of these affected, data of the antibody titers solely reinforces the vaccination resolution made beforehand and thus doesn’t contribute to a change in vaccination resolution. The specifically-requested symptom of cutaneous hyperesthesia throughout COVID-19 an infection was unexpectedly frequent.

omniscientis
omniscientis
Anti-VEGF antibody
STJ119887 100 µl
EUR 393
Description: This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.
VEGF-KDR, Peptide Aptamer, FITC labelled
AP-337-F 1 mg Ask for price
Crotalus adamanteus Snake venom metalloproteinase adamalysin-2
1-CSB-EP330325DYB
  • EUR 611.00
  • EUR 309.00
  • EUR 1827.00
  • EUR 939.00
  • EUR 1218.00
  • EUR 397.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 27.1 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 expressed in E.coli
Anti-VEGF/VEGF164 Antibody
A00045-1 100ug/vial
EUR 294
Anti-VEGF/Vegfa Antibody
A00045-2 100ug/vial
EUR 294
Anti-VEGF-C Antibody
A00623 100ul
EUR 397
Description: Rabbit Polyclonal Antibody for VEGF-C Antibody (VEGFC) detection.tested for IHC, WB in Human, Mouse, Rat.
Anti-VEGF/VEGFA Antibody
PB9071 100ug/vial
EUR 334
Anti-VEGF/VEGFA Antibody
PA1080 100ug/vial
EUR 334
Anti-VEGF-B antibody
STJ96851 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF-B.
Anti-VEGF-C antibody
STJ96662 200 µl
EUR 197
Description: Rabbit polyclonal to VEGF-C.
anti-VEGF Receptor 1
YF-PA11817 50 ug
EUR 363
Description: Mouse polyclonal to VEGF Receptor 1
anti-VEGF Receptor 1
YF-PA11818 100 ug
EUR 403
Description: Rabbit polyclonal to VEGF Receptor 1
anti-VEGF Receptor 3
YF-PA23727 50 ul
EUR 334
Description: Mouse polyclonal to VEGF Receptor 3
Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug
7422-MSM1-P1 100ug
EUR 428
Polyclonal Goat anti-GST α-form
GST-ANTI-1 50 uL
EUR 280
Polyclonal Goat anti-GST μ-form
GST-ANTI-2 50 uL
EUR 280
Polyclonal Goat anti-GST p-form
GST-ANTI-3 50 uL
EUR 280
Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin
1-CSB-EP606027NAH
  • EUR 611.00
  • EUR 309.00
  • EUR 1827.00
  • EUR 939.00
  • EUR 1218.00
  • EUR 397.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
  • MW: 50.7 kDa
  • Buffer composition: Tris-based buffer with 50% glycerol.
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli
anti-Apolipoprotein F
YF-PA10244 50 ul
EUR 363
Description: Mouse polyclonal to Apolipoprotein F
anti-Apolipoprotein F
YF-PA10245 50 ug
EUR 363
Description: Mouse polyclonal to Apolipoprotein F
anti-Apolipoprotein F
YF-PA10246 100 ug
EUR 403
Description: Rabbit polyclonal to Apolipoprotein F
anti-Cathepsin F
YF-PA15821 50 ul
EUR 363
Description: Mouse polyclonal to Cathepsin F
anti-Cathepsin F
YF-PA15822 50 ug
EUR 363
Description: Mouse polyclonal to Cathepsin F
anti-Cyclophilin F
YF-PA25484 50 ul
EUR 334
Description: Mouse polyclonal to Cyclophilin F
VEGF receptor Flt-1 (F56), Peptide Aptamer, FITC labelled
AP-334-F 1 mg Ask for price
Anti-VEGF (Bevacizumab), humanized Antibody
A1045-100
EUR 501
Anti-VEGF Rabbit Monoclonal Antibody
M00045-1 100ug/vial
EUR 397
Description: Rabbit Monoclonal VEGF Antibody. Validated in Flow Cytometry, IP, IF, IHC, ICC and tested in Human, Mouse.
Anti-VEGF Receptor 3 (5F11)
YF-MA13094 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 3 (6F9)
YF-MA13095 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 3 (5B5)
YF-MA13096 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 3 (4D1)
YF-MA13097 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 3 (2E3)
YF-MA13098 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 3 (1C1)
YF-MA13099 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 3 (6B7)
YF-MA13100 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Anti-VEGF Receptor 2 (2A2)
YF-MA13909 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2
Anti-VEGF Receptor 2 (4A2)
YF-MA13910 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2
Anti-VEGF Receptor 2 (2C5)
YF-MA13911 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2
Anti-VEGF Receptor 2 (4B5)
YF-MA13912 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2
Anti-VEGF Receptor 2 (4F1)
YF-MA13913 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 2
Anti-VEGF-A Humanized Antibody
A2136-100 100 µg
EUR 510
Anti-VEGF Receptor 3 (5B6)
YF-MA10355 100 ug
EUR 363
Description: Mouse monoclonal to VEGF Receptor 3
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-b-48T 48T
EUR 493
  • Should the Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-b-96T 96T
EUR 641
  • Should the Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma or other biological fluids.
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Hu-48T 48T
EUR 336
  • Should the Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Hu-96T 96T
EUR 425
  • Should the Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Mu-48T 48T
EUR 435
  • Should the Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Mu-96T 96T
EUR 561
  • Should the Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Ra-48T 48T
EUR 454
  • Should the Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
DLR-EG-VEGF-Ra-96T 96T
EUR 587
  • Should the Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-b-48Tests 48 Tests
EUR 516
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-b-96Tests 96 Tests
EUR 716
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Hu-48Tests 48 Tests
EUR 330
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Hu-96Tests 96 Tests
EUR 450
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Mu-48Tests 48 Tests
EUR 447
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Mu-96Tests 96 Tests
EUR 618
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Ra-48Tests 48 Tests
EUR 470
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RDR-EG-VEGF-Ra-96Tests 96 Tests
EUR 651
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-b-48Tests 48 Tests
EUR 494
Bovine Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-b-96Tests 96 Tests
EUR 684
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Hu-48Tests 48 Tests
EUR 317
Human Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Hu-96Tests 96 Tests
EUR 431
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Mu-48Tests 48 Tests
EUR 429
Mouse Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Mu-96Tests 96 Tests
EUR 591
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Ra-48Tests 48 Tests
EUR 450
Rat Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) ELISA Kit
RD-EG-VEGF-Ra-96Tests 96 Tests
EUR 622
VEGF
PR15028 10 ug
EUR 461
VEGF
MO15067 500 ug
EUR 910
VEGF
LF-PR009 10 ug
EUR 255
Description: VEGF protein
VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, FITC labelled
AP-336-F 1 mg Ask for price
VEGF receptor KDR and Flt-1 (v107), Peptide Aptamer, FITC labelled
AP-335-F 1 mg Ask for price
VEGF-stimulated Human Umbilical Vein Endothelial Cell, Peptide Aptamer, FITC labelled
AP-338-F 1 mg Ask for price
VEGF-stimulated human umbilical vein endothelial cells, Peptide Aptamer, FITC labelled
AP-339-F 1 mg Ask for price
VEGF-A(VEGF/1063) Antibody
BNC611063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC611063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC401063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC401063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC431063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC431063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC471063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC471063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC551063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC551063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC051063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC051063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC041063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC041063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNUB1063-100 100uL
EUR 209
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL
VEGF-A(VEGF/1063) Antibody
BNUB1063-500 500uL
EUR 458
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL
VEGF-A(VEGF/1063) Antibody
BNUM1063-50 50uL
EUR 395
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC681063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC681063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC701063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC701063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC941063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC941063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF594 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCH1063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCH1063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC801063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC801063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCP1063-250 250uL
EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCR1063-250 250uL
EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCA1063-250 250uL
EUR 383
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCAP1063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCAP1063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCB1063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNCB1063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC881063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC881063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC811063-100 100uL
EUR 199
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL
VEGF-A(VEGF/1063) Antibody
BNC811063-500 500uL
EUR 544
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL
VEGF/ Rat VEGF ELISA Kit
ELA-E0143r 96 Tests
EUR 886
Anti-VEGF Receptor 1/FLT1 Antibody
A00534 100ug/vial
EUR 294
Anti-VEGF Receptor 1/FLT1 Antibody
A00534-1 100ug/vial
EUR 294
Anti-VEGF Receptor 2/KDR Antibody
A00901-2 100ug/vial
EUR 334
Anti-VEGF Receptor 2/Kdr Antibody
A00901-3 100ug/vial
EUR 334
Anti-VEGF Receptor 3/FLT4 Antibody
A01276-2 100ug/vial
EUR 334
Anti-VEGF Receptor 3/FLT4 Antibody
A01276-3 100ug/vial
EUR 334
Anti-VEGF Receptor 2/KDR Antibody
PB9429 100ug/vial
EUR 294
Anti-VEGF Receptor 1/FLT1 Antibody
PA1399 100ug/vial
EUR 294
Anti-VEGF Receptor 1/FLT1 Antibody
PA1966 100ug/vial
EUR 294
Anti-VEGF Receptor 1/FLT1 Antibody
PA1966-1 100ug/vial
EUR 294
Anti-VEGF Receptor 1/FLT1 Antibody
PA1966-2 100ug/vial
EUR 294
Anti-VEGF Receptor 2/KDR Antibody
PA1989 100ug/vial
EUR 334
anti- Cathepsin F antibody
FNab01307 100µg
EUR 505.25
  • Immunogen: cathepsin F
  • Uniprot ID: Q9UBX1
  • Research Area: Metabolism
Description: Antibody raised against Cathepsin F
anti- Cystatin F antibody
FNab02182 100µg
EUR 548.75
  • Recommended dilution: WB: 1:200-1:2000
  • IHC: 1:20-1:200
  • Immunogen: cystatin F(leukocystatin)
  • Uniprot ID: O76096
  • Research Area: Metabolism
Description: Antibody raised against Cystatin F
anti- HLA-F antibody
FNab03911 100µg
EUR 585
  • Recommended dilution: WB: 1:200-1:2000
  • IHC: 1:20-1:200
  • Immunogen: major histocompatibility complex, class I, F
  • Uniprot ID: P30511
  • Gene ID: 3134
  • Research Area: Immunology
Description: Antibody raised against HLA-F
anti- HLA-F antibody
FNab03912 100µg
EUR 585
  • Immunogen: major histocompatibility complex, class I, F
  • Uniprot ID: P30511
  • Gene ID: 3134
  • Research Area: Immunology
Description: Antibody raised against HLA-F
Anti-Cyclin F Antibody
A06781 100ul
EUR 397
Description: Rabbit Polyclonal Cyclin F Antibody. Validated in IHC, WB and tested in Human.
Anti-HLA-F Purified
11-823-C100 0.1 mg
EUR 195
Anti-HLA-F PE
1P-823-C100 0.1 mg
EUR 331
Anti-Cathepsin F antibody
PAab01307 100 ug
EUR 355
Anti-Cystatin F antibody
PAab02182 100 ug
EUR 386
Anti-HLA-F antibody
PAab03911 100 ug
EUR 412
Anti-HLA-F antibody
PAab03912 100 ug
EUR 412
Anti-APOBEC3D/F antibody
STJ91636 200 µl
EUR 197
Description: Rabbit polyclonal to APOBEC3D/F.
Anti-Arylsulfatase F antibody
STJ91715 200 µl
EUR 197
Description: Rabbit polyclonal to Arylsulfatase F.
Anti-Cyclin F antibody
STJ92545 200 µl
EUR 197
Description: Rabbit polyclonal to Cyclin F.
Anti-Cyclophilin F antibody
STJ92550 200 µl
EUR 197
Description: Rabbit polyclonal to Cyclophilin F.
Anti-F beta antibody
STJ93162 200 µl
EUR 197
Description: Rabbit polyclonal to FTbeta.
Anti-hnRNP F antibody
STJ93564 200 µl
EUR 197
Description: Rabbit polyclonal to hnRNP F.
Anti-PIG-F antibody
STJ95089 200 µl
EUR 197
Description: Rabbit polyclonal to PIG-F.
Anti-Cathepsin F antibody
STJ70694 100 µg
EUR 359
Anti-Apolipoprotein F antibody
STJ71651 100 µg
EUR 359
Anti-HLA-F antibody
STJ24030 100 µl
EUR 277
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain.
Anti-HLA-F antibody
STJ112420 100 µl
EUR 277
Description: This gene belongs to the HLA class I heavy chain paralogues. It encodes a non-classical heavy chain that forms a heterodimer with a beta-2 microglobulin light chain, with the heavy chain anchored in the membrane. Unlike most other HLA heavy chains, this molecule is localized in the endoplasmic reticulum and Golgi apparatus, with a small amount present at the cell surface in some cell types. It contains a divergent peptide-binding groove, and is thought to bind a restricted subset of peptides for immune presentation. This gene exhibits few polymorphisms. Multiple transcript variants encoding different isoforms have been found for this gene. These variants lack a coding exon found in transcripts from other HLA paralogues due to an altered splice acceptor site, resulting in a shorter cytoplasmic domain.
Anti-Apolipoprotein F (1D5)
YF-MA10047 100 ug
EUR 363
Description: Mouse monoclonal to Apolipoprotein F
Mouse IgG F(c)-FITC conjugate (isotype control)
20008-Fc-F 100 ug
EUR 164
Rabbit IgG F(c)-FITC conjugate, isotype control
20009-Fc-F 100 ug
EUR 164
Goat IgG F(ab')2 fragment-FITC conjugate
20011-FAB2-F 100 tests
EUR 202
Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA
570-100-CUX Custom Ask for price
Mouse IgG F(ab')2-FITC conjugate (isotype control)
20008-Fab2-F 100 ug
EUR 164
Rabbit IgG F(ab')2-FITC conjugate, isotype control
20009-FAb2-F 100 ug
EUR 164
VEGF Antibody
AF5131 200ul
EUR 304
Description: VEGF Antibody detects endogenous levels of total VEGF.
VEGF Antibody
ABF5131 100 ug
EUR 438
VEGF antibody
70R-VG001 100 ug
EUR 327
Description: Affinity purified Goat polyclonal VEGF antibody
VEGF antibody
70R-VR001x 50 ug
EUR 327
Description: Affinity purified Rabbit polyclonal VEGF antibody
VEGF antibody
70R-VR003 50 ug
EUR 273
Description: Affinity purified Rabbit polyclonal VEGF antibody
VEGF antibody
70R-VR004 50 ug
EUR 273
Description: Affinity purified Rabbit polyclonal VEGF antibody
VEGF antibody
70R-VR006 50 ug
EUR 273
Description: Affinity purified Rabbit polyclonal VEGF antibody
VEGF Antibody
5363-100
EUR 332
VEGF Antibody
5363-30T
EUR 146
VEGF Antibody
5365-100
EUR 316
VEGF Antibody
5365-30T
EUR 146
VEGF Antibody
48707-100ul 100ul
EUR 333
VEGF Antibody
48707-50ul 50ul
EUR 239
VEGF antibody
10-2585 250 ug
EUR 492
Description: Mouse monoclonal VEGF antibody
VEGF antibody
10-2586 100 ug
EUR 241
Description: Mouse monoclonal VEGF antibody
VEGF antibody
10R-7735 500 ug
EUR 565
Description: Mouse monoclonal VEGF antibody
VEGF antibody
10R-V101ax 100 ug
EUR 476
Description: Mouse monoclonal VEGF antibody
VEGF antibody
10R-V101b 200 ug
EUR 671
Description: Mouse monoclonal VEGF antibody
VEGF antibody
10R-V109A 500 ug
EUR 273
Description: Mouse monoclonal VEGF antibody
VEGF protein
30R-AV008 2 ug
EUR 127
Description: Purified recombinant Murine VEGF protein
VEGF antibody
70R-11863 100 ul
EUR 447
Description: Goat polyclonal VEGF antibody
VEGF antibody
70R-11864 100 ug
EUR 403
Description: Rabbit polyclonal VEGF antibody
VEGF antibody
70R-12327 100 ug
EUR 403
Description: Rabbit polyclonal VEGF antibody
VEGF antibody
70R-12328 100 ug
EUR 403
Description: Rabbit polyclonal VEGF antibody
VEGF antibody
70R-12329 100 ug
EUR 403
Description: Rabbit polyclonal VEGF antibody
VEGF antibody
70R-13764 100 ug
EUR 349
Description: Affinity purified Rabbit polyclonal VEGF antibody
VEGF antibody
70-VR20 50 ug
EUR 327
Description: Affinity purified Rabbit polyclonal VEGF antibody
VEGF, CF
PR15028CF 10 ug
EUR 461
VEGF 121
PR15029 5 ug
EUR 415
VEGF 162
PR15030 25 ug
EUR 461
VEGF 165
PR15031 50 ug
EUR 1231

 

Engineering a novel IgG-like bispecific antibody towards enterovirus A71

 

Frequent outbreaks of enterovirus A71 (EVA71) happen within the Asia-Pacific space, and these are carefully related to extreme neurological signs in younger kids. No efficient antiviral remedy is at present accessible for the therapy of EVA71 an infection. The event of monoclonal antibodies (mAbs) has demonstrated promise as a novel remedy for the prevention and therapy of infectious illnesses. A number of medical situations have been handled utilizing bispecific or multi-specific antibodies that acknowledge two or extra distinct epitopes concurrently. Nevertheless, bispecific or multi-specific antibodies typically encounter protein expression and product stability issues.

On this research, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral exercise in contrast with E18 or F1. Moreover, E18-F1 not solely improved survival price, but in addition decreased medical indicators in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a deadly dose of EVA71. Altogether, our outcomes reveal that E18-F1 is a straightforward format bispecific antibody with promising antiviral exercise for EVA71.

Excessive antibody ranges towards human herpesvirus-6A work together with life-style elements in a number of sclerosis growth

 

Background: An infection with human herpesvirus 6A (HHV-6A) has been instructed to extend a number of sclerosis (MS) danger. Nevertheless, potential interactions between HHV-6A and environmental/life-style danger elements for MS haven’t beforehand been studied.

Strategies: We used two Swedish population-based case-control research comprising 5993 circumstances and 5995 controls. Utilizing logistic regression fashions, topics with completely different HHV-6A antibody ranges, environmental exposures, and life-style habits have been in contrast concerning MS danger, by calculating odds ratios (ORs) with 95% confidence intervals (CIs). Potential interactions between excessive HHV-6A antibody ranges and customary environmental exposures and life-style elements have been evaluated on the additive scale.

Outcomes: Excessive HHV-6A antibody ranges have been related to elevated danger of creating MS (OR = 1.5, 95% CI = 1.4-1.6). Concerning MS danger, vital interactions have been noticed between excessive HHV-6A antibody ranges and each smoking (attributable proportion (AP) = 0.2, 95% CI = 0.1-0.3), low ultraviolet radiation (UVR) publicity (AP = 0.3, 95% CI = 0.1-0.4), and low vitamin D ranges (AP = 0.3, 95% CI = 0.0-0.6).

Conclusion: Excessive HHV-6A antibody ranges are related to elevated MS danger and act synergistically with widespread environmental/life-style danger elements for MS. Additional analysis is required to analyze potential mechanisms underlying the interactions introduced on this research.

 

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *